Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.47 |
| ▸ | DRD2 | P14416 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 11/20 | 0.47 |
| ▸ | HTR7 | P34969 | 11/20 | 0.47 |
| ▸ | HTR6 | P50406 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479341 | 0.84 | KMT2A (0.57) | KMT2ALMNAMAPTMAPK1HTT | |
| SCHEMBL4479907 | 0.83 | PRKCQ (0.50) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL4477617 | 0.83 | MAPT (0.42) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4476877 | 0.80 | KMT2A (0.42) | HTR7NPC1RAB9AKMT2ALMNA | |
| SCHEMBL4490150 | 0.80 | MAPT (0.42) | CDK2KMT2AMEN1LMNAMAPT | |
| SCHEMBL4469214 | 0.79 | KMT2A (0.46) | NPC1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL4475566 | 0.79 | MAPT (0.60) | KMT2ALMNAMAPTMAPK1HTT | |
| SCHEMBL4491193 | 0.78 | PRKCQ (0.48) | HTR7HTR6NPC1RAB9AKMT2A | |
| SCHEMBL4467715 | 0.78 | KMT2A (0.48) | NPC1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL4470722 | 0.78 | NPY1R (0.43) | KMT2AMEN1LMNAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | HTR1A 3668/4885DRD2 2565/4885HTR2A 3380/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | HTR1A 3668/4885DRD2 2565/4885HTR2A 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.